An Introduction to Multiple Myeloma
Despite numerous advances in the last decade, multiple myeloma remains an incurable disease, characterised by relapses that ultimately result in uncontrolled disease and death. However, novel agents, such as proteasome inhibitors, immunomodulatory drugs and CD38-directed monoclonal antibodies, have substantially improved survival and tolerability. These emerging agents include immune checkpoint inhibitors and chimeric antigen receptor-engineered T-cell therapies, although eventual relapse remains an issue.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Multiple Myeloma Content
Melflufen—A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma
Oncology & Hematology Review (US). 2020; 16(1):12–4 DOI: https://doi.org/10.17925/OHR.2020.16.1.12
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma.1 Although recent decades have seen considerable advances and improvements in clinical outcomes for patients with MM,2 MM remains incurable, with a high disease burden.3 Clonal evolution and genomic instability within myeloma clones inevitably lead to disease progression and treatment resistance.4 An increasing number […]
Current management of relapsed/refractory multiple myeloma and the future integration of BCMA-targeting agents
Watch a panel of internationally renowned multiple myeloma experts discuss the management of relapsed/refractory disease and the future for B-cell maturation antigen (BCMA)-targeted agents
- Discuss how treatment for patients with relapsed/refractory multiple myeloma can be selected based on disease- and patient-related factors
- Describe the rationale for B-cell maturation antigen (BCMA) as a treatment target and current agents in development
- Recall the latest data for BCMA-targeting agents in relapsed/refractory multiple myeloma and consider how they may be incorporated into clinical practice
María-Victoria Mateos, EHA 2020: TOURMALINE-MM4 study
Dr María-Victoria Mateos, (Associate Professor of Medicine, Director of Myeloma Unit, University Hospital of Salamanca, Salamanca, Spain) explores unmet needs in the treatment of patients with newly-diagnosed multiple myeloma, and discusses the major findings of the TOURMALINE-MM4 study and the potential of ixazomib in patients no undergoing autologous stem cell transplant. Questions: What are the limitations […]
BMCA-targeting agents in relapsed/refractory multiple myeloma: Distilling the data from the ASCO Annual Meeting 2020
Find out about the latest data on the use of B-cell maturation antigen (BCMA)-targeted therapies in the management of relapsed/refractory multiple myeloma through our touchCONGRESS Webinar and Expert Interviews with European experts discussing data from ASCO20 Virtual.
- Discuss the need for new treatment options for relapsed/refractory multiple myeloma and the rationale for targeting B-cell maturation antigen (BCMA)
- Describe the latest efficacy data for BCMA-targeting agents and evaluate how they may be integrated into the current treatment pathway
- Describe the latest safety data for BCMA-targeting agents and consider how adverse events could be managed in clinical practice
Biomarkers and novel therapies in relapsed/refractory multiple myeloma: Where are we heading in 2020?
Watch leading expert Prof. Graham Jackson discuss the importance of identifying high-risk patients with relapsed/refractory multiple myeloma and the role of biomarkers and novel therapies in optimizing individual patient care.
- Identify those patients with relapsed/refractory multiple myeloma with the most significant unmet needs
- Describe existing and novel biomarker testing and the relevance for optimizing the treatment of relapsed/refractory multiple myeloma
- Discuss the evidence for novel treatments and the potential for further treatment optimization with combination treatments in clinical trials and practice
Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma
We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]
Patrick Laroche, ASCO20: Bispecific Antibodies in the Treatment of Multiple Myeloma
Patrick Laroche, EMEA Therapeutic Area Leader Hematology at Janssen Pharmaceutica, discusses the benefits of new bispecific antibodies and how he sees the future of multiple myeloma treatment evolving over the coming years. Click here to view Patrick Laroche discussing the potential of CAR-T treatment JNJ-4528 in multiple myeloma Questions 1. Could you tell us more […]
Patrick Laroche, ASCO20: The Potential of CAR-T Treatment JNJ-4528 in Multiple Myeloma
Patrick Laroche, EMEA Therapeutic Area Leader Hematology at Janssen Pharmaceutica, discusses the unmet needs in multiple myeloma treatment and the potential of CAR-T treatment JNJ-4528 in helping to overcome some of the challenges. Click here to view Patrick Laroche discussing bispecific antibodies in the treatment of multiple myeloma. Questions 1. What are the current unmet […]
Jesus G Berdeja, ASCO20: Updated Results from the Phase Ib/II CARTITUDE-1 Trial
Jesus G Berdeja, Director of myeloma research at Sarah Cannon Research Institute, discusses the updated results from the Phase Ib/II CARTITUDE-1 trial, which were presented at ASCO20. The study assesses the efficacy and safety of CAR-T treatment JNJ-4528 in heavily pre-treated patients with multiple myeloma. Questions 1. What are the current unmet needs in CAR-T […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!